The TP53-LGALS4 axis modulates the tumor immune microenvironment and synergizes with anti PD-L1 therapy in colorectal cancer
Collectively, these findings demonstrate a novel role for TP53-mediated LGALS4 in regulating tumor progression. This work identifies LGALS4 as a promising therapeutic target and provides a foundation for the development of combined immunotherapy based on galectin for CRC.
Authors
- Renchao Deng
- J W Li
- Houjie Liang
- Dapeng Zhang (ORCID: https://orcid.org/0000-0003-4222-6107)
- Meng Yang (ORCID: https://orcid.org/0000-0003-0063-7100)
- Lili Zhang
- Qing Qin
- Xiaoqing Peng
- Fan Zhang
- Yulan Huang
Institutions
- Army Medical University (CN)
- Chongqing University (CN)
- People's Hospital of Bishan District (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Southwest Hospital (CN)
- Chongqing Emergency Medical Center (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1186/s12967-025-07598-6
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 0.00